Visual hallucination in Parkinson's disease with FDG PET

被引:73
|
作者
Nagano-Saito, A
Washimi, Y
Arahata, Y
Iwai, K
Kawatsu, S
Ito, K
Nakamura, A
Abe, Y
Yamada, T
Kato, T
Kachi, T
机构
[1] Natl Ctr Geriatr & Gerontol, Dept Brain Sci & Mol Imaging, Natl Inst Longev Sci, Obu, Aichi 4748522, Japan
[2] Chubu Natl Hosp, Dept Neurol, Obu, Japan
关键词
Parkinson's disease; visual hallucination; F-18]fluorodeoxyglucose; FDG; positron emission tomography (PET);
D O I
10.1002/mds.20129
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To determine the characteristics of cerebral glucose metabolism in Parkinson's disease patients with visual hallucinations, group comparison studies using [F-18]fluorodeoxyglucose positron emission tomography were performed. Nondemented Parkinson's disease patients in advanced stages were classified into two groups: (1) patients without visual hallucinations; (2) patients with visual hallucinations. Compared to patients without hallucinations. the relative regional cerebral glucose metabolic rate was greater in the frontal areas in patients with visual hallucinations, and the increase reached a significant level in the left superior frontal gyrus. Relative frontal hypermetabolism may be a feature of Parkinson's disease patients with visual hallucinations. (C) 2004 Movement Disorder Society.
引用
收藏
页码:801 / 806
页数:6
相关论文
共 50 条
  • [41] Cerebral metabolic change in Parkinson's disease patients with anxiety: A FDG-PET study
    Wang, Xixi
    Zhang, Jiejin
    Yuan, Yongsheng
    Li, Tiannv
    Zhang, Li
    Ding, Jian
    Jiang, Siming
    Li, Junyi
    Zhu, Lin
    Zhang, Kezhong
    NEUROSCIENCE LETTERS, 2017, 653 : 202 - 207
  • [42] Cognitive and Behavior Deficits in Parkinson's Disease with Alteration of FDG-PET Irrespective of Age
    Lauretani, Fulvio
    Ruffini, Livia
    Testa, Crescenzo
    Salvi, Marco
    Scarlattei, Mara
    Baldari, Giorgio
    Zucchini, Irene
    Lorenzi, Beatrice
    Cattabiani, Chiara
    Maggio, Marcello
    GERIATRICS, 2021, 6 (04)
  • [43] FDG PET Parkinson's disease-related pattern as a biomarker for clinical trials in early stage disease
    Matthews, Dawn C.
    Lerman, Hedva
    Lukic, Ana
    Andrews, Randolph D.
    Mirelman, Anat
    Wernick, Miles N.
    Giladi, Nir
    Strother, Stephen C.
    Evans, Karleyton C.
    Cedarbaum, Jesse M.
    Even-Sapir, Einat
    NEUROIMAGE-CLINICAL, 2018, 20 : 572 - 579
  • [44] PET and SPECT in Parkinson's disease
    Blesa, R
    REVISTA DE NEUROLOGIA, 1997, 25 : S147 - S150
  • [45] PET Imaging in Parkinson's disease
    Dhawan, Vijay
    Eidelberg, David
    CURRENT MEDICAL IMAGING, 2007, 3 (04) : 233 - 241
  • [46] Auditory and visual hallucination prevalence in Parkinson's disease and dementia with Lewy bodies: a systematic review and meta-analysis
    Eversfield, Charlotte Louise
    Orton, Llwyd David
    PSYCHOLOGICAL MEDICINE, 2019, 49 (14) : 2342 - 2353
  • [47] Lateral geniculate atrophy in Parkinson's with visual hallucination: A trans-synaptic degeneration?
    Lee, Jee-Young
    Yoon, Eun Jin
    Lee, Woong Woo
    Kim, Yu Kyeong
    Lee, Jun-Young
    Jeon, Beomseok
    MOVEMENT DISORDERS, 2016, 31 (04) : 547 - 554
  • [48] FDG PET in Alzheimer's disease subtypes
    Herholz, Karl
    INTERNATIONAL PSYCHOGERIATRICS, 2013, 25 : S27 - S27
  • [49] Parkinson's disease and Huntington's disease by PET and MRI
    Piccini, P.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 21 - 22
  • [50] The role of FDG-PET in pre-operative evaluation of Parkinson's disease and effect of pallidotomy
    Giroux, ML
    Vitek, JL
    Grafton, ST
    Delong, MR
    Hoffman, JM
    NEUROLOGY, 1997, 48 (03) : 4096 - 4096